Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1

Interventions

Rituximab 52 Cyclophosphamide 42 fludarabine phosphate 41 Peripheral Blood Stem Cell Transplantation 41 Whole-Body Irradiation 26 Mycophenolic Acid 25 Cyclosporine 21 Bortezomib 21 Dexamethasone 19 Busulfan 18 Tacrolimus 17 Etoposide 17 Filgrastim 15 Antilymphocyte Serum 14 Methotrexate 13 Melphalan 13 ibrutinib 12 Radiotherapy 11 Calcium Dobesilate 9 Sirolimus 8 Lenalidomide 8 Cyclosporins 8 Methylprednisolone 7 Flow Cytometry 7 Everolimus 7 Carboplatin 7 ibritumomab tiuxetan 6 zanubrutinib 5 fludarabine 5 Transplantation 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Waldenstrom Macroglobulinemia × Lisaftoclax × Clear all

NCT04260217 2025-08-19

MAPLE-1

Ascentage Pharma Group Inc.

Phase 1 Completed

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡